22 results about "Glucokinase" patented technology

The present disclosure relates to a combination therapy comprising a first AAV vector genome comprising an insulin expression cassette; and a second AAV vector genome comprising a glucokinase expression cassette; wherein the first AAV vector genome and the second AAV vector genome are in a ratio selected from the group consisting of 1:0.25-0.75, 1:1.75-2.25, and 1:3.75-4.25, and methods for using the same for treating diabetes.

The invention relates to a hyaluronic acid high-yield strain based on metabolic flow optimization as well as a construction method and application thereof, and belongs to the technical field of genetic engineering. According to the corynebacterium glutamicum, sources of key rate-limiting enzymes UDP-glucose dehydrogenase and glutamine-fructose-6-phosphate aminotransferase are screened, and heterologous expression of hyaluronic acid synthase and overexpression of endogenous inositol permease and glucokinase are combined, so that the corynebacterium glutamicum capable of highly producing hyaluronic acid is constructed in a form of optimizing metabolic flux; according to the invention, the hyaluronic acid is used as a substrate, polyhydroxybutyrate synthase clusters are further overexpressed in the substrate, the glucose uptake and utilization efficiency of a host are improved, the metabolic coupling of cofactors is realized, the yield of the hyaluronic acid reaches 45g / L, the production intensity is 1.25 g / L / h, a brand new tool is provided for the production of the hyaluronic acid, and the method has an excellent application prospect.

This invention relates to a blackcurrant and orange juice mixed soft drink, belonging to the field of beverage technology. The mixed soft drink contains blackcurrant extract, orange juice, white hyacinth bean seed extract, mogrosides, steviol glycosides, etc. The blackcurrant extract is a product with a lower than 5kDa obtained by enzymatic hydrolysis of blackcurrants with hemicellulase and pectinase, followed by sequential enzymatic hydrolysis with nattokinase, fig protease, papain, and glucokinase. The white hyacinth bean seed extract is a product with a lower than 5kDa obtained by trypsin hydrolysis of white hyacinth bean seeds, followed by co-fermentation with Propionibacterium finigense, Lactobacillus brevis, and Bifidobacterium longum. The blackcurrant extract and white hyacinth bean seed extract have excellent anti-fatigue, antioxidant, and immune-enhancing effects, making the mixed soft drink both delicious and healthy.

Described are compositions and methods for inhibition of glucokinase (GCK) gene expression and protein production. RNA interference (RNAi) agents for inhibiting the expression of GCK gene are described. The GCK RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more GCK RNAi agents optionally with one or more additional therapeutics are also described.

The invention relates to a composition for producing a fermented milk product comprising: (i) a starter culture comprising a glucose-fermenting Streptococcus thermophilus (St) strain and a glucose-fermenting Lactobacillus delbrueckii subsp. bulgaricus (Lb) strain; and (ii) a glucose-deficient Streptococcus thermophilus (St) strain, wherein said St strain is galactose-fermenting and carries a mutation in the DNA sequence of the glcK gene encoding a glucokinase protein, which mutation inactivates the glucokinase protein or has a negative effect on expression of the gene.

Providing modified insulin and glucokinase nucleic acids for treating diabetes SOLUTION: Reducing hyperglycaemia and maintaining euglycaemia are the goals of all therapeutic approaches to the T1DM and T2DM. Current therapy for most diabetics is based on regular subcutaneous injections of both short-acting and long-acting insulin preparations. The present disclosure relates to modified nucleic acid sequences encoding insulin and glucokinase, expression cassettes and delivery vectors comprising the same, and methods for their delivery to treat diabetes.SELECTED DRAWING: None

The present invention relates to a microorganism belonging to the genus Corynebacterium and having improved L-lysine production capacity, and a method for producing L-lysine using the same, the microorganism being capable of producing L-lysine by enhancing the activity of a glucose-promoting diffusion transporter and a glucokinase. Therefore, the production yield of L-lysine can be improved compared with the condition of enhancing the parent strain, the glucose promoting diffusion transporter or the glucokinase alone.

Described are compositions and methods for inhibition of glucokinase (GCK) gene expression and protein production. RNA interference (RNAi) agents for inhibiting the expression of GCK gene are described. The GCK RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more GCK RNAi agents optionally with one or more additional therapeutics are also described.

The application discloses application of polyphosphate-dependent glucokinase in glycosylation modification of pentacyclic triterpenoid compounds, a sugar group donor of the glycosylation modification is sucrose, the polyphosphate-dependent glucokinase is used for converting byproduct fructose into fructose-6-phosphate, and the polyphosphate-dependent glucokinase is CgPPGK with an amino acid sequence as shown in SEQ ID NO:1 or Asp-PPGK with an amino acid sequence as shown in SEQ ID NO:2. The polyphosphate-dependent glucokinase CgPPGK or Asp-PPGK is coupled to a traditional UDP-glucose regeneration system in the application, a coupled three-enzyme UDP-glucose regeneration system is formed, consumption of fructose is realized, more UDP-glucose is generated in the reaction, glycosylation efficiency and sucrose utilization rate are improved, and the glycosylation modification capacity for a substrate is obviously higher than that of an original traditional UDP-glucose regeneration system.

Described are compositions and methods for inhibition of glucokinase (GCK) gene expression and protein production. RNA interference (RNAi) agents for inhibiting the expression of GCK gene are described. The GCK RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more GCK RNAi agents optionally with one or more additional therapeutics are also described.

The invention relates to a construction and fermentation method of recombinant corynebacterium glutamicum for high-yield indigoidine, and the recombinant corynebacterium glutamicum is obtained by taking corynebacterium glutamicum as an original strain and transforming one or more of A-D items; the method comprises the following steps: A, knocking out a gene for coding glucose transporter on a genome, and integrating a glucose permease gene and a glucokinase gene; b, knocking out a gene for coding gamma-glutamyl kinase on a genome, and integrating a glk gene at the same time; c, overexpressing an ornamental blue synthetase gene and a 4 '-phosphopantetheinyl transferase gene; and D: overexpressing a glutamine synthetase gene, an alpha-ketoglutarate dehydrogenase inhibiting enzyme gene, a glutamate dehydrogenase gene and an isocitrate dehydrogenase gene. According to the method, glutamine can be efficiently converted, the yield of the indigoidine is greatly increased, and a foundation is laid for industrial production of the indigoidine.

The invention discloses a glucose metabolism reconstruction-based engineering strain for efficiently synthesizing rhamnolipid and a construction method thereof, the construction method comprises the following steps: taking pseudomonas putida KT2440 or a flag gene cluster knockout strain thereof as an original strain, optimizing the genome of the original strain through gene modification, and introducing recombinant plasmids to obtain the engineering strain for efficiently synthesizing rhamnolipid; the modification comprises at least one of (1) to (6): (1) heterologous expression of rhamnolipid synthesis related genes; (2) replacing the rmlA gene with the gene rmlA *; (3) knocking out related genes for coding Gad; (4) heterologous expression of a galP gene encoding glucose transporter protein; (5) heterologous expression of the glf gene encoding the glucose transporter; and (6) overexpressing and coding the glk gene of glucokinase. The method disclosed by the invention has the beneficial effects that efficient directional distribution of glucose to a rhamnolipid synthesis route is realized, and the synthesis efficiency of the rhamnolipid is remarkably improved.

The present invention relates to specific uses of lactose-positive Streptococcus thermophilus strains in cheese production. The strains used in accordance with the present invention can carry one or more mutations in the glcK gene encoding a glucokinase, which mutations induce a reduction in glucokinase activity, carry mutations in the ccpA gene, and / or carry mutations in at least one of the genes encoding a mannose-glucose specific PTS protein. The invention further relates to compositions comprising a strain of the invention used according to the invention in combination with at least one strain of Lactobacillus and / or one strain of Mesophilic Lactobacillus, methods for making cheese, and cheese obtained by these methods.

The invention discloses an N-acetylglucosamine transferase mutant and application thereof in production of L-tryptophan, and belongs to the technical field of genetic engineering. In order to solve the problems of yield limitation and the like caused by excessive consumption of phosphoenolpyruvic acid in the production of L-tryptophan, the invention weakens a phosphoprotein coding gene crr on escherichia coli; meanwhile, a uridine diphosphate galactose pyranose mutase gene glf and a glucokinase gene glk of the pseudomonas mobilis and an endogenous galactose H (+) transporter enzyme gene galP of escherichia coli are integrated at a pflB site, and a genetically engineered bacterium is obtained; mutagenesis is carried out on the basis to obtain a mutant strain with improved L-tryptophan yield; and the N-acetylglucosamine transferase mutants nagC and nagE are obtained by virtue of sequencing. Fermentation proves that overexpression of the mutant nagC or nagE or simultaneous overexpression of the mutants nagC and nagE in the genetically engineered bacteria can improve the yield of L-tryptophan.

The present disclosure relates to modified nucleic acid sequences encoding insulin and glucokinase, expression cassettes and delivery vectors comprising the same, and methods for delivery of the same for treating diabetes.

The present invention discloses a recombinant engineering bacterium of Escherichia coli for producing citicoline and a construction method and application thereof, belonging to the field of biotechnology; Escherichia coli K‑12 MG1655-based knockout of the genomic cytidine deaminase gene cdd The temperature-controlled expression vector PBV220 was used to express SpnCCT‑SpnCKI‑pRpLpyrG Mutating the gene cluster enhances the expression of the choline transporter BetT and disrupts Escherichia coli ptsH‑ptsI‑ crr locus, and simultaneously introduced from Zymomonas mobilis ( Zymomonas mobilis ) glucose permease gene glf and glucokinase genes glk , and obtained the recombinant Escherichia coli ZMCB02NCL capable of efficiently biosynthesizing citicoline, with the deposit number being CCTCC NO: M 2025483.

The present disclosure relates to modified nucleic acid sequences encoding insulin and glucokinase, expression cassettes and delivery vectors comprising the same, and methods of delivering them to treat diabetes. Certain embodiments are directed to a polynucleotide encoding a human insulin protein, the polynucleotide comprising: (i) a nucleotide sequence encoding a signal peptide, where optionally, the signal peptide is not a wild-type preproinsulin signal sequence; and (ii) a nucleotide sequence encoding a proinsulin polypeptide comprising an amino acid modification at a position selected from amino acids B10, B28, and / or B29 of the human insulin B chain, C1 and / or C32 of the human insulin C chain, or any combination thereof, relative to the corresponding amino acid position in wild-type proinsulin; and optionally, the polynucleotide further comprises a cleavage site.

This invention discloses a method for constructing a zebrafish model of fatty liver based on glucokinase overexpression and its application. The method includes the following steps: using cDNA as a template, a zebrafish GCK gene fragment is obtained by PCR amplification; the vector fragment and the GCK gene fragment are homologously recombined using a homologous recombinase to obtain a recombinant plasmid; the recombinant plasmid is transformed into competent cells, and an endotoxin-free plasmid is extracted as a zebrafish GCK expression vector; a microinjection system is used to inject the plasmid into one-cell-stage fertilized eggs; after the fertilized eggs hatch into juveniles, fluorescent juveniles are selected for further culture until sexual maturity; sexually mature males and females are paired to spawn, and a stably heritable GCK-overexpressing zebrafish strain is selected from the offspring. This invention can obtain a zebrafish strain with stable high GCK expression, which can be used as a zebrafish model of fatty liver based on GCK overexpression.

The invention discloses a glucokinase mutant for enhancing the glucose utilization rate of escherichia coli and application of the glucokinase mutant. The invention belongs to the technical field of biology, and particularly relates to a glucokinase mutant for enhancing the glucose utilization rate of escherichia coli and application of the glucokinase mutant. The mutant protein disclosed by the invention is any one of the following proteins: 1) a protein obtained by mutating the 142 A of a sequence 1 into V or L and keeping other amino acid residues unchanged; 2) a protein obtained by mutating R in the 188th sequence of the sequence 1 into H and keeping other amino acid residues unchanged; and 3) a protein obtained by mutating the 142 of the sequence 1 into V or L, mutating R of the 188 of the sequence 1 into H and keeping other amino acid residues unchanged. The encoding gene of glucokinase in receptor escherichia coli is knocked out, and the encoding gene of mutant protein is introduced into the receptor escherichia coli, so that the enzyme activity of the obtained recombinant escherichia coli is 7.3 times that of wild escherichia coli, and the glucose utilization rate of escherichia coli is increased.

Use of glycerol monodecanoate in preparing a medicament for treating hyperglycemia or diabetes or a functional food for assisting in lowering blood glucose associated with hyperglycemia or diabetes. Glycerol monodecanoate reduces blood glucose by promoting the expression of the glucokinase gene and the insulin receptor gene in the liver glycolysis pathway and inhibiting the expression of the phosphoenolpyruvate carboxyl kinase gene and the glucose-6-phosphatase catalytic subunit gene in the gluconeogenesis pathway.

The present invention relates to a microorganism of the genus Corynebacterium with an improved ability to produce L-lysine and a method for producing L-lysine, using same. The microorganism of the genus Corynebacterium exhibits enhanced activities of a glucose-facilitated diffusion transporter and glucokinase, and thus can have improved L-lysine production yield as compared to a parent strain or cases where a glucose-facilitated diffusion transporter or glucokinase is enhanced alone.

The invention belongs to the technical field of bioengineering, and relates to a recombinant engineering bacterium and application thereof in preparation of mannitol, and the recombinant engineering bacterium is a plasmid-free strain for producing a cofactor NAD < + > by using cheap xylose and nicotinamide. The following genes are knocked out from the strain: a gene ptsG for coding protein EIICBGlc in a glucose PTS system, mtlA for coding EIICA protein in D-mannitol transmembrane transport, a D-mannitol 1-phosphate dehydrogenase gene mtlD in a D-mannitol utilization path, purine de novo synthesis regulation protein purR, and srlAE in a sorbitol utilization gene cluster. The following genes are integrated in a genome of the strain: glucose transport assisting protein glf, glucokinase glcK, xylose utilization gene cluster xylose isomerase xlyA and xylulose phosphorylase xlyB, phosphoribose pyrophosphate synthetase prs, polyphosphate kinase ppk2, nicotinamide phosphoribose transferase nadV and nicotinamide mononucleotide adenylate transferase nadM. The strain is fermented by using glucose and xylose, and provides chassis bacteria for reaction needing cofactor circulation.